Coronavirus Disease 2019-Associated Mucormycosis in France: A Rare but Deadly Complication

Abstract We studied COVID-19 associated mucormycosis based on 17 cases reported nationwide and assessed the differences with India. They differed by frequencies of diabetes mellitus (47% in France versus up to 95% in India), hematological malignancies (35% versus 1%), anatomical sites (12% versus &g...

Full description

Saved in:
Bibliographic Details
Published inOpen forum infectious diseases Vol. 9; no. 2; p. ofab566
Main Authors Danion, François, Letscher-Bru, Valérie, Guitard, Juliette, Sitbon, Karine, Dellière, Sarah, Angoulvant, Adela, Desoubeaux, Guillaume, Botterel, Francoise, Bellanger, Anne-Pauline, Gargala, Gilles, Uhel, Fabrice, Bougnoux, Marie-Elisabeth, Gerber, Victor, Michel, Justin, Cornu, Marjorie, Bretagne, Stéphane, Lanternier, Fanny
Format Journal Article
LanguageEnglish
Published US Oxford University Press 01.02.2022
Subjects
Brief Report
Communicable diseases
Coronaviruses
Diabetes
France
Health aspects
India
Life Sciences
Microbiology and Parasitology
Mortality
Mucormycosis
Posaconazole
Virology
France
India
CAPA
COVID-19
mucormycosis
CAM
Online AccessGet full text

Cover

More Information
Summary:Abstract We studied COVID-19 associated mucormycosis based on 17 cases reported nationwide and assessed the differences with India. They differed by frequencies of diabetes mellitus (47% in France versus up to 95% in India), hematological malignancies (35% versus 1%), anatomical sites (12% versus >80% rhino-orbito-cerebral) and prognosis (88% mortality versus <50%). We reported 17 cases of COVID-19 associated mucormycosis in France. Compared to India, they differed by frequencies of diabetes mellitus (47% versus up to 95% in India), hematological malignancies (35% versus 1%), anatomical sites and mortality (88% versus <50%).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMCID: PMC8773954
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofab566